BEDFORD, Mass., Nov. 1, 2010 /PRNewswire/ — Hologic, Inc.
(Hologic or the Company) (Nasdaq:
HOLX), a leading developer, manufacturer and supplier of
premium diagnostics products, medical imaging systems and surgical
products dedicated to serving the healthcare needs of women, today
announced the long-term, five-year results from the American
Society of Breast Surgeons (ASBS) MammoSite® Breast
Brachytherapy Registry Trial (ASBS Registry) while showcasing the
MammoSite ML (multi-lumen) system at the 52nd ASTRO (American
Society for Radiation Oncology) Annual Meeting in San Diego October
31 through November 4, 2010. The ASBS Registry Trial
represents the largest compilation of MammoSite patients to date
and demonstrates promising results for breast cancer
patients. The MammoSite system is the only breast
brachytherapy balloon with five-year efficacy data. Of the
1,449 patients (1,440 treated) with early-stage breast cancer, 37
patients had an ipsilateral breast tumor recurrence (IBTR), for a
five-year actuarial rate of 3.80 percent. A subset analysis
of the first 400 consecutive cases had a median follow-up of 60.5
months and demonstrated a five-year actuarial rate of IBTR of 3.04
percent.
According to Frank Vicini, M.D., principal investigator of the
study, “The data are promising and add further clinical support for
the use of accelerated partial breast irradiation in appropriate
patients.”
Carter Houghton, Vice President and General Manager of Hologic’s
Interventional Breast Solutions business, added, “The five-year
ASBS Registry findings are a significant milestone for the
MammoSite technology. Good local cancer control rates and
cosmetic results are critical outcomes in breast cancer therapy.
We look forward to expanding the utilization of accelerated
partial breast irradiation by breast cancer patients that may have
p
‘/>”/>
SOURCE